Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
The current Regeneron(REGN) stock price is $736.50, with a market capitalization of 75.75B. The stock trades at a price-to-earnings (P/E) ratio of 18.17 and offers a dividend yield of 0.50%.
During the trading session on 2026-10-03, Regeneron(REGN) shares reached a daily high of $742.50 and a low of $729.20. At a current price of $736.50, the stock is +1.0% higher than the low and still -0.8% under the high.
Trading volume for Regeneron(REGN) stock has reached 612.9K, versus its average volume of 770.41K.
Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $541.00.
Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $541.00.
REGN News
Regeneron Pharmaceuticals (REGN) just expanded its long-running immunology alliance with Sanofi, securing a US$1b upfront payment and potential milestones up to...
...
Jefferies raised the firm’s price target on Regeneron (REGN) to $930 from $870 and keeps a Buy rating on the shares. The company’s expanded collaboration with S...
Analyst ratings
63%
of 30 ratingsMore REGN News
Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Sanofi and Regeneron have completed a new real-world stud...
Regeneron (REGN) Pharmaceuticals announced the first results for the investigational ubamatamab in patients with low-grade serous ovarian cancer. The data are f...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) are expanding their extensive, two-decade-long antibody partnership to jointly develop a...
Argus upgraded Regeneron (REGN) to Buy from Hold with an $850 price target The recent share pullback provides an attractive entry point, the analyst tells inves...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced an expansion of their long-standing antibody collaboration, adding multiple next-generation, long-ac...
A prior litigation related to the collaboration was settled as part of the agreement, the companies said. Sylvain Thomas / Agence France-Presse / Getty Images...
Sanofi ( (FR:SAN) ) has issued an update. Sanofi and Regeneron have expanded their two-decade immunology alliance by adding four next-generation, long-acting a...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.